Prospective Observational Study of Filgotinib in Participants With Rheumatoid Arthritis in France
NCT ID: NCT05323591
Last Updated: 2025-12-10
Study Results
The study team has not published outcome measurements, participant flow, or safety data for this trial yet. Check back later for updates.
Basic Information
Get a concise snapshot of the trial, including recruitment status, study phase, enrollment targets, and key timeline milestones.
ACTIVE_NOT_RECRUITING
155 participants
OBSERVATIONAL
2022-05-03
2026-07-31
Brief Summary
Review the sponsor-provided synopsis that highlights what the study is about and why it is being conducted.
Related Clinical Trials
Explore similar clinical trials based on study characteristics and research focus.
Prospective Observational Study of Filgotinib in Subjects With Rheumatoid Arthritis
NCT04871919
Long Term Extension Study to Assess the Safety and Efficacy of Filgotinib in Adults With Rheumatoid Arthritis
NCT03025308
Study to Assess the Safety and Tolerability of MEDI5117 in Rheumatoid Arthritis Patients
NCT01559103
A Study Evaluating the Effect of Filgotinib in Participants With Active Axial Spondyloarthritis
NCT05785611
An Observational Study of RoActemra/Actemra (Tocilizumab) in Rheumatoid Arthritis Patients
NCT01615419
Detailed Description
Dive into the extended narrative that explains the scientific background, objectives, and procedures in greater depth.
Conditions
See the medical conditions and disease areas that this research is targeting or investigating.
Study Design
Understand how the trial is structured, including allocation methods, masking strategies, primary purpose, and other design elements.
COHORT
PROSPECTIVE
Study Groups
Review each arm or cohort in the study, along with the interventions and objectives associated with them.
Filgotinib
Participants will receive treatment for moderate to severe active RA with at least one dose of filgotinib in accordance with the product label.
Filgotinib
Tablets are administered in accordance with the product label
Interventions
Learn about the drugs, procedures, or behavioral strategies being tested and how they are applied within this trial.
Filgotinib
Tablets are administered in accordance with the product label
Other Intervention Names
Discover alternative or legacy names that may be used to describe the listed interventions across different sources.
Eligibility Criteria
Check the participation requirements, including inclusion and exclusion rules, age limits, and whether healthy volunteers are accepted.
Inclusion Criteria
* Female participants of childbearing potential must agree to use contraception while taking filgotinib as per product label.
* Participants must be willing and able to use an electronic device to complete the study PROs.
* Participant must sign and date the Informed Consent Form (ICF) before enrollment into the study.
Exclusion Criteria
* Female participant is pregnant or intending to become pregnant while taking filgotinib.
18 Years
ALL
No
Sponsors
Meet the organizations funding or collaborating on the study and learn about their roles.
Alfasigma S.p.A.
INDUSTRY
Responsible Party
Identify the individual or organization who holds primary responsibility for the study information submitted to regulators.
Principal Investigators
Learn about the lead researchers overseeing the trial and their institutional affiliations.
Alfasigma Study Director
Role: STUDY_DIRECTOR
Alfasigma S.p.A.
Locations
Explore where the study is taking place and check the recruitment status at each participating site.
CHU Amiens Picardie site Nord
Amiens, , France
CHU de Amiens Picardie
Amiens, , France
Hopital Avicenne AP-HP
Bobigny, , France
CHU Bordeaux
Bordeaux, , France
CH de Cahors
Cahors, , France
Clinique de l'Infirmerie Protestante de Lyon
Caluire-et-Cuire, , France
Hopital Sud Francilien Corbeil Essonne
Corbeil-Essonnes, , France
Hopital Roger Salengro
Lille, , France
CHU de Nice
Nice, , France
Centre Hospitalier Régional d'Orléans
Orléans, , France
Hopital Saint Antoine
Paris, , France
Hopital Cochin Service A
Paris, , France
Hopital Robert Debre
Reims, , France
CHU de Rouen
Rouen, , France
Centre Hospitalier Universitaire de Saint Etienne
Saint-Etienne, , France
CHU Toulouse
Toulouse, , France
CHRU de Tours
Tours, , France
Countries
Review the countries where the study has at least one active or historical site.
Other Identifiers
Review additional registry numbers or institutional identifiers associated with this trial.
49028
Identifier Type: OTHER
Identifier Source: secondary_id
GLPG0634-CL-424
Identifier Type: -
Identifier Source: org_study_id
More Related Trials
Additional clinical trials that may be relevant based on similarity analysis.